The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin

References

• Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States, 2014. Atlanta (GA): US Department of Health and Human Services; 2014 [cited 2015 Jun 25]. Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.
   Google Scholar
• Centers for Disease Control and Prevention. Diabetes Public Health Resource. Rate per 100 of Civilian, Noninstitutionalized Population with Diagnosed Diabetes, by Age, United States, 1980–2011. Atlanta (GA): US Department of Health and Human Services; 1980–2011 [cited 2015 Jun 25]. Available from: http://www.cdc.gov/diabetes/statistics/prev/national/figbyage.htm.
   Google Scholar
• Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care. 1998;21(2):296–309.
   PubMed Web of Science ®Google Scholar
• Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med. 2013;45(3):253–261.
   PubMed Web of Science ®Google Scholar
• Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514–1523.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2015. Diabetes Care. 2015;38(Suppl 1):S1–S92.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21:438–447.
   PubMed Web of Science ®Google Scholar
• Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):2271–2279.
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086.
   PubMed Web of Science ®Google Scholar
• Davies M, Storms F, Shutler S, et al. ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28(6):1282–1288.
   PubMed Web of Science ®Google Scholar
• Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab Res Rev. 2014;30(2):104–119.
   PubMed Web of Science ®Google Scholar
• Levien TL, Baker DE, White JR Jr, et al. Insulin glargine: a new basal insulin. Ann Pharmacother. 2002;36(6):1019–1027.
   PubMed Web of Science ®Google Scholar
• Goykhman S, Drincic A, Desmangles JC, et al. Insulin glargine: a review 8 years after its introduction. Expert Opin Pharmacother. 2009;10(4):705–718.
   PubMed Web of Science ®Google Scholar
• Rotenstein LS, Ran N, Shivers JP, et al. Opportunities and challenges for biosimilars: what’s on the horizon in the global insulin market? Clin Diabetes. 2012;30(4):138–150.
   Google Scholar
• Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716–1730.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408–416.
   PubMed Web of Science ®Google Scholar
• Sanofi. Press release: Sanofi receives FDA approval of once-daily basal insulin Toujeo®. 2015 Feb 26 [cited 2015 Jun 25]. Available from: http://hugin.info/152918/R/1897483/673465.pdf.
   Google Scholar
• Dahmen R, Bergmann K, Lehmann A, et al. New insulin glargine U300 formulation evens and prolongs steady state PK and PD profiles during euglycemic clamp in patients with type 1 diabetes (T1DM) [abstract 113-OR]. Diabetes. 2013;62(Suppl 1):A29.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–2762.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235–3243.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386–394.
   PubMed Web of Science ®Google Scholar
• Aye MM, Atkin SL. Patient safety and minimizing risk with insulin administration – role of insulin degludec. Drug Healthc Patient Saf. 2014;6:55–67.
   PubMedGoogle Scholar
• Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–1507.
   PubMed Web of Science ®Google Scholar
• Onishi Y, Iwamoto Y, Yoo SJ, et al. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013;4(6):605–612.
   PubMed Web of Science ®Google Scholar
• Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464–2471.
   PubMed Web of Science ®Google Scholar
• Kennedy L, Herman WH, Strange P, et al. GOAL AIC Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29(1):1–8.
   PubMed Web of Science ®Google Scholar
• Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol. 2007;1(4):540–548.
   PubMedGoogle Scholar
• Shaefer C, Traylor L, Gao L, et al. Exploratory study of a dose-response curve for basal insulin. Diabetes. 2015;64(S1):A253 [ Abstract 995-P].
   Google Scholar
• Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508–2514.
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 2006;12(Suppl 1):42–46.
   PubMedGoogle Scholar
• Shaefer C, Reid T, DiGenio A, et al. Is assessment of postprandial hyperglycaemia useful in determining whether to initiate prandial therapy after basal insulin fails to achieve glycaemic control? [abstract 1021]. Diabetologia. 2013;56(Suppl 1):S410.
   Google Scholar
• Reid T, Gao L, Gill J, et al. How much is too much? Outcomes in patients using high-dose insulin glargine [abstract 915-P]. Diabetes. 2014;63(Suppl 1):A234.
   Google Scholar
• Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med. 2009;122(6 Suppl):S37–S50.
   PubMed Web of Science ®Google Scholar
• Edelman S, Pettus J. Challenges associated with insulin therapy in type 2 diabetes mellitus. Am J Med. 2014;127(10 Suppl):S11–S16.
   PubMed Web of Science ®Google Scholar
• Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA. 2014;311(22):2315–2325.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682–689.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673–2679.
   PubMed Web of Science ®Google Scholar
• Skyler JS. Current therapy of diabetes mellitus. DeFronzo RA, editor. St Louis (MO): Mosby; 1998. p. 108–116.
   Google Scholar
• Galloway JA, Chance RE. Improving insulin therapy: achievements and challenges Horm Metab Res. 1994;26(12):591–598.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Ligthelm R, Christiansen JS, et al. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab. 2007;9(5):630–639.
   PubMed Web of Science ®Google Scholar
• Giugliano D, Chiodini P, Maiorino MI, et al. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine. Epub 2015 Aug 18.
   Google Scholar
• Riddle MC. Making the transition from oral to insulin therapy. Am J Med. 2005;118(Suppl 5A):14S–20S.
   PubMed Web of Science ®Google Scholar
• Jang HC, Guler S, Shestakova M. PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract. 2008;62(7):1013–1018.
   PubMed Web of Science ®Google Scholar
• Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28(2):254–259.
   PubMed Web of Science ®Google Scholar
• Petznick A. Insulin management of type 2 diabetes mellitus. Am Fam Physician. 2011;84(2):183–190.
   PubMed Web of Science ®Google Scholar
• White JR Jr, Campbell RK, Hirsch IB. Novel insulins and strict glycemic control. Analogues approximate normal insulin secretory response. Postgrad Med. 2003;113(6):30–36.
   PubMed Web of Science ®Google Scholar
• Freeman JS. Insulin analog therapy: improving the match with physiologic insulin secretion. J Am Osteopath Assoc. 2009;109(1):26–36.
   PubMedGoogle Scholar
• Lloyd A, Nafees B, Barnett AH, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Ther. 2011;33(9):1258–1267.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Gao L, Vlajnic A. Clinical characteristics and outcomes of T2DM patients adding 1 to 3 stepwise prandial insulin doses to basal insulin and oral therapy: identifying a problematic subgroup [abstract 14-OR]. Diabetes. 2012;61(Suppl 1):A4.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Vlajnic A, et al. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab. 2014;16(5):396–402.
   PubMed Web of Science ®Google Scholar
• MannKind Corporation. Press release: Sanofi and MannKind announce Afrezza®, the only inhaled insulin, now available in the U.S. 2015 Feb 3 [cited 2015 Jun 25]. Available from: http://www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-newsArticle&ID=2012895.
   Google Scholar
• Santos Cavaiola T, Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther. 2014;36(8):1275–1289.
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742.
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Schneider D, King A, et al. A short-acting GLP-1 analog or prandial insulin to supplement basal insulin? – Moving toward personalized management of type 2 diabetes mellitus. Postgrad Med. 2014;126(3):135–144.
   PubMed Web of Science ®Google Scholar
• Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103–112.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36(9):2497–503.
   PubMed Web of Science ®Google Scholar
• Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):855–893.
   PubMed Web of Science ®Google Scholar
• Gough SC, Buse JB, Woo VC, et al. One-year efficacy and safety of IDegLira in patients with type 2 diabetes [abstract 65-OR]. Diabetes. 2014;63(Suppl 1):A17.
   Google Scholar
• Rosenstock J, Diamant M, Silvestre L, et al. Benefits of a fixed-ratio formulation of once-daily insulin glargine/lixisenatide (LixiLan) vs. glargine in type 2 diabetes (T2DM) inadequately controlled on metformin [abstract 332-OR]. Diabetes. 2014;63(Suppl 1):A87.
   Google Scholar
• Kumar A. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy. Expert Opin Biol Ther. 2014;14(6):869–878.
   PubMed Web of Science ®Google Scholar
• Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385(9982):2057–2066.
   PubMed Web of Science ®Google Scholar
• Artigas CF, Stokes V, Tan GD, et al. Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice. Expert Opin Pharmacother. 2015;16(10):1417–1421.
   PubMed Web of Science ®Google Scholar
• Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384(9961):2228–2234.
   PubMed Web of Science ®Google Scholar
• Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med. 1922;7(5):251–266.
   Google Scholar